The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells
Thiazolidinediones (TZDs) dramatically reduce the growth of human prostate cancer cells in vitro and in vivo. To determine whether the antitumor effects of TZDs were due in part to changes in the MEK/Erk signaling pathway, we examined the regulation of Erk phosphorylation by the TZD troglitazone wit...
Saved in:
Main Authors: | Adrienne Bolden, Lynikka Bernard, Danielle Jones, Tunde Akinyeke, LaMonica V. Stewart |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2012/929052 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
by: Tamotsu Tsukahara
Published: (2012-01-01) -
PPARγ and Its Agonists in Chronic Kidney Disease
by: Yuhua Ma, et al.
Published: (2020-01-01) -
PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
by: Sarawin Harnchoowong, et al.
Published: (2017-01-01) -
Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
by: Ajit A. Kulkarni, et al.
Published: (2012-01-01) -
New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
by: Zhanjun Jia, et al.
Published: (2014-01-01)